Navidea and Collaborator Molecular Neuroimaging Enroll First Subject in NAV5001 Clinical Trial

... is the first leg of our program to evaluate the utility of NAV5001 in DLB, the leading form of dementia after Alzheimer's disease and an important potential indication for NAV5001 medically and commercially," commented Cornelia Reininger, MD, PhD, ...

http://www.businesswire.com/news/topix/20130403006197/en